Your browser is no longer supported. Please, upgrade your browser.
CMTA Clementia Pharmaceuticals Inc. daily Stock Chart
Clementia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-4.30 Insider Own- Shs Outstand31.21M Perf Week6.92%
Market Cap568.96M Forward P/E- EPS next Y-1.39 Insider Trans- Shs Float26.46M Perf Month49.30%
Income-115.50M PEG- EPS next Q-0.33 Inst Own91.40% Short Float1.05% Perf Quarter10.02%
Sales- P/S- EPS this Y-309.20% Inst Trans24.09% Short Ratio3.42 Perf Half Y12.53%
Book/sh9.73 P/B1.87 EPS next Y-0.70% ROA-117.10% Target Price27.00 Perf Year-
Cash/sh2.12 P/C8.59 EPS next 5Y- ROE427.50% 52W Range11.72 - 20.15 Perf YTD-3.95%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-9.53% Beta-
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low55.55% ATR1.31
Employees30 Current Ratio10.70 Sales Q/Q- Oper. Margin- RSI (14)61.68 Volatility6.55% 8.19%
OptionableNo Debt/Eq0.00 EPS Q/Q58.20% Profit Margin- Rel Volume0.21 Prev Close18.60
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 Payout- Avg Volume80.76K Price18.23
Recom1.30 SMA2015.35% SMA5013.31% SMA20010.91% Volume16,774 Change-1.99%
Mar-16-18 08:15AM  Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-06-18 06:30AM  Clementia to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-28-18 04:05PM  Clementia Reports 2017 Operating Results and Business Highlights GlobeNewswire +11.78%
Feb-07-18 06:30AM  Clementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Jan-31-18 06:30AM  Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors GlobeNewswire
Jan-03-18 06:30AM  Clementia Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference GlobeNewswire -7.36%
Dec-12-17 06:30AM  Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva GlobeNewswire
Dec-05-17 06:30AM  Clementia Announces Date of Corporate Update Conference Call GlobeNewswire
Nov-13-17 08:00AM  Clementia Reports Third Quarter 2017 Financial Results and Business Highlights GlobeNewswire
Oct-20-17 11:16AM  Have Investors Already Priced In Healthcare Growth For Clementia Pharmaceuticals Inc (CMTA)? Simply Wall St.
Aug-06-17 09:36AM  IPOs This Week: Coal, Oilfield Services, and Pharma Offerings on Tap 24/7 Wall St.
Aug-02-17 12:15PM  Clementia Pharma Enters the Market With a Bang 24/7 Wall St.
06:00AM  Clementia Announces Pricing of Initial Public Offering PR Newswire
06:00AM  Clementia Announces Pricing of Initial Public Offering CNW Group
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. The company is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.